Published in PLoS One on January 29, 2014
Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia (2016) 0.75
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget (2016) 0.75
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med (2003) 6.82
Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 6.24
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol (2002) 3.33
B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science (2012) 3.03
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood (2006) 2.77
B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol (2001) 2.55
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood (2002) 2.37
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 2.36
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14
B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2011) 2.11
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med (2008) 1.95
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest (2005) 1.93
A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia (2004) 1.83
Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases. Sci Signal (2013) 1.73
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood (1996) 1.35
Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radic Biol Med (2002) 1.34
Single-cell mass cytometry adapted to measurements of the cell cycle. Cytometry A (2012) 1.33
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene (2009) 1.30
When and how to treat chronic lymphocytic leukemia. N Engl J Med (2000) 1.12
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res (2010) 1.04
Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer (2010) 1.03
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood (2012) 1.01
Cell-to-cell variability analysis dissects the plasticity of signaling of common γ chain cytokines in T cells. Sci Signal (2013) 0.97
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol (2004) 0.84
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. BMC Cancer (2012) 0.82
Diversity training for signal transduction: leveraging cell-to-cell variability to dissect cellular signaling, differentiation and death. Curr Opin Biotechnol (2013) 0.79